WebISB 1442 Lands FDA Orphan Drug Status for R/R Multiple Myeloma. By Jordyn Sava. March 22nd 2024. ISB 1442, a 2+1 biparatopic bispecific antibody that has CD38 and CD47 targeting domains, has received an orphan drug designation from the FDA and is being assessed in a phase 1/2 clinical trial for patients with multiple myeloma. WebCiteScore排名 CiteScore SJR SNIP ; 学科: 排名: 百分位: 3.39: 1.322: 0.862: Medicine Pharmacology (medical) 40 / 232: 82%
Breast Cancer_影响因子(IF)_中科院分区_SCI期刊投稿经验_爱科学
WebAug 9, 2024 · 影响因子是衡量期刊水平的重要指标,一般而言,影响因子较高的期刊投稿命中率较低,相对较难中,而影响因子较低的期刊则相对容易发表,为方便大家投稿时选刊,耐特译根据影响因子高低对各个学科期刊进行了排名,供大家投稿时参考。. 血液学(HEMATOLOGY ... WebApr 5, 2024 · Targeted Oncology. Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. Recently, a better … Targeted Oncology addresses physicians and scientists committed to oncology … Targeted Oncology will consider high-quality original research studies with a … new terminal newark airport
Bethesda Handbook Of Clinical Oncology 3rd Edition
Web《Targeted Oncology》发布于爱科学网,并永久归类相关SCI期刊导航类别中,本站只是硬性分析 "《TARGET ONCOL》" 杂志的可信度。学术期刊真正的价值在于它是否能为科技进 … WebCANCER JOURNAL. 出版年份:2000 年文章数:2 投稿命中率:62.5%. 出版周期:Bimonthly 自引率:0.2% 审稿周期:平均3月. 前往期刊查询. 期刊讨论 中国SCI论文 期刊主页 投 … Web7总结. 《Journal for ImmunoTherapy of Cancer》 免疫学领域期刊总的看来实力不俗,影响因子起点高,三年内即接近10分,自引率也不高。. 奇葩的地方是发文量忽高忽低,而且数量相差大 ,出版时间也飘忽不定,国人发文量廖廖,几乎可忽略,所以今天这本期刊各位 ... new terminator models